NEWSROOM Stay current with MiRXES Newsrooms > Media Releases MiRXES strengthens global fight against cancer with launch of world’s first research project for a multi-cancer screening test using microRNA and multi-omics technology SINGAPORE, 7 July 2022 – MiRXES Pte Ltd, a Singapore-headquartered biotechnology company, whose mission is to save and improve lives through early, actionable, …
NEWSROOM Stay current with MiRXES Newsrooms > Media Releases MiRXES – BGI Research – MGI Strategic Partnership to Scale Cutting-Edge Spatial Multi-Omics Research Capabilities in Asia-Pacific Region SINGAPORE, 7 June 2022 – MiRXES, a Singapore-headquartered biotechnology company, whose mission is to save and improve lives through early, actionable, and personalized diagnoses, announced today that it …
NEWSROOM Stay current with MiRXES Newsroom > Media Releases MiRXES Opens Southeast Asia’s First Industry 4.0 In Vitro Diagnostic Manufacturing Facility Singapore, 27 May 2022 – MiRXES Pte Ltd, a Singapore-headquartered biotechnology company, and A*STAR spinoff, focused on saving and improving lives with miRNA-powered cancer early detection tests, announced today the opening of the first …
NEWSROOM Stay current with MiRXES Newsroom > Media Releases MiRXES announces appointment of Dan Headon as Senior Vice President, Marketing SINGAPORE, 15 November 2021 – MiRXES Pte Ltd, a Singapore-headquartered biotechnology company focused on improving and saving lives with RNA-powered disease early detection tests, announced today the appointment of Mr. Dan HEADON as Senior Vice …
MiRXES announces appointment of Dan Headon as Senior Vice President, Marketing Read More »
NEWSROOM Stay current with MiRXES Newsroom > Media Releases MiRXES’s Founders Named EY Entrepreneur Of The Year 2021 Singapore SINGAPORE, 22 November 2021 – MiRXES Pte Ltd, a Singapore-headquartered biotechnology company focused on improving and saving lives with RNA-powered disease early detection tests, announced today that Dr. Lihan ZHOU, Co-founder and Chief Executive Officer at …
MiRXES’s Founders Named EY Entrepreneur Of The Year 2021 Singapore Read More »
NEWSROOM Stay current with MiRXES Newsroom > Media Releases MiRXES enters Hong Kong led by newly appointed Managing Director, Martin Law SINGAPORE / HONG KONG, 15 February 2022 – MiRXES Pte Ltd, a Singapore-headquartered biotechnology company focused on improving and saving lives with RNA-powered cancer early detection tests, announced today the set-up of its Hong …
MiRXES enters Hong Kong led by newly appointed Managing Director, Martin Law Read More »
NEWSROOM Stay current with MiRXES Newsroom > Media Releases MiRXES Welcomes Professor Tony Mok to Scientific Advisory Board SINGAPORE, 12 April 2022 – MiRXES Pte Ltd, a Singapore-headquartered biotechnology company focused on improving and saving lives with miRNA-powered cancer early detection tests, announced today the appointment of Professor Tony Mok, a world-renowned medical oncologist, to …
MiRXES Welcomes Professor Tony Mok to Scientific Advisory Board Read More »
NEWSROOM Stay current with MiRXES Newsroom > Media Releases Yayasan MENDAKI and MiRXES announce SG$140,000 MENDAKI – MiRXES scholarship scheme for undergraduate and post-graduate students SINGAPORE, 23 October 2021 – Yayasan MENDAKI (“MENDAKI”) and MiRXES Pte Ltd (“MiRXES”), a Singapore-headquartered biotechnology company focused on improving and saving lives with RNA-powered disease early detection tests, are …
NEWSROOM Stay current with MiRXES Newsroom > Media Releases MiRXES appoints Cher Hwa Teo as Senior Vice President, Health Innovation Delivery and Chief of Staff SINGAPORE, 1 October 2021 – MiRXES Pte Ltd, a Singapore-headquartered biotechnology company focused on improving and saving lives with RNA-powered disease early detection tests, announced today the appointment of Mr. …
NEWSROOM Stay current with MiRXES Newsroom > Media Releases MiRXES Board of Directors welcomes strategic investor Da Liu from CR-CP Life Science Fund to fast-track groundbreaking early cancer diagnostics Board appointment coincides with an additional US$10 million capital injection into MiRXES from private equity CDG Capital and NHH Ventures SINGAPORE, 21 September 2021 – MiRXES …
